Physician profile
Raphael Waknine
NPI 1306855903
$1,351.20
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $119.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $387.90 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $240.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $182.54 | 2019-2020 | |
| Alkermes, INC. | $182.49 | 2019 | |
| Vanda Pharmaceuticals INC. | $88.79 | 2019-2020 | |
| Lundbeck LLC | $88.14 | 2019 | |
| Neurocrine Biosciences, INC. | $87.70 | 2019 | |
| Allergan, INC. | $42.30 | 2019 | |
| Indivior INC. | $29.45 | 2019 | |
| Glaxosmithkline, LLC. | $21.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Waknine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.